Back to News
Market Impact: 0.55
Novo says its next-gen obesity drug tops Lilly rival in late-stage study
Source: reuters.com
Healthcare & BiotechCompany FundamentalsAntitrust & Competition
Novo Nordisk said its next-generation experimental obesity drug delivered estimated average weight loss of 12.4% in a late-stage trial. The company said the treatment outperformed Eli Lilly's competing drug, strengthening Novo's competitive position in the high-growth weight-loss medicines market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
LLY-0.45
NVO0.78
More News
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
- Iran & China at Forefront of Trading Week, Critical Metals Rally & NVO Slides
- Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals
- Dow opens 407 pts higher as oil, yields ease ahead of Trump‑Xi summit
- Why Novo Nordisk Stock Just Crashed
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper